Seinäjoki Central Hospital, Hanneksenrinne 7, 60220, Seinäjoki, Finland.
Turku University Hospital, Turku, Finland.
Tech Coloproctol. 2020 Mar;24(3):215-220. doi: 10.1007/s10151-020-02148-2. Epub 2020 Jan 21.
The aim of this study was to report the outcomes of sacral neuromodulation (SNM) in chronic pelvic pain (CPP) patients in the Finnish national cohort.
This was a register-based retrospective study, involving all the centers that provide SNM treatment in Finland. The data of all patients treated with SNM for CPP were gathered from Oulu-, Turku-, Tampere- and Helsinki University Hospitals, as well as Jyväskylä and Seinäjoki Central Hospitals. All patients who had been tested for SNM implantation prior to April 2017 were included in the study.
A total of 51 patients were selected for SNM treatment due to CPP from 2004 until 2017. The mean follow-up time was 13.8 months (SD 22.9 months). A total of 28 patients (57%) advanced from testing to permanent stimulator implantation. There were 21 patients (41%) who had a working modulator implanted at the end of follow-up. Patients with endometriosis-related pain had a significantly higher permanent implantation rate than the overall implantation rate (88% vs. 57%; p = 0.01). The endometriosis patients also had a higher overall success rate by the end of the follow-up (75% vs. 41%; p = 0.026) CONCLUSIONS: SNM may be a viable treatment option for patients with CPP due to endometriosis. Further research on SNM treatment for endometriosis patients with refractory CPP is needed.
本研究旨在报告芬兰全国队列中慢性盆腔痛(CPP)患者接受骶神经调节(SNM)治疗的结果。
这是一项基于注册的回顾性研究,涉及芬兰所有提供 SNM 治疗的中心。从奥卢、图尔库、坦佩雷和赫尔辛基大学医院以及于韦斯屈莱和塞纳约基中央医院收集了所有接受 SNM 治疗 CPP 的患者的数据。所有在 2017 年 4 月之前接受过 SNM 植入测试的患者均纳入本研究。
2004 年至 2017 年期间,共有 51 名 CPP 患者因该疾病接受了 SNM 治疗。平均随访时间为 13.8 个月(SD 22.9 个月)。共有 28 名患者(57%)从测试期转为永久性刺激器植入。在随访结束时有 21 名患者(41%)植入了工作刺激器。与子宫内膜异位症相关疼痛的患者永久性植入率明显高于总体植入率(88%比 57%;p=0.01)。在随访结束时,子宫内膜异位症患者的总体成功率也更高(75%比 41%;p=0.026)。
SNM 可能是子宫内膜异位症相关 CPP 患者的一种可行治疗选择。需要进一步研究 SNM 治疗难治性 CPP 的子宫内膜异位症患者。